Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

S. Segal; I. Y. Shemesh; R. Blumenthal; B. Yoffe; N. Laufer; Y. Ezra; I. Levy; M. Mazor; U. Martinowitz

doi:10.1007/s00404-002-0409-1

Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

S. Segal^*
, I. Y. Shemesh
, R. Blumenthal
, B. Yoffe
, N. Laufer
, Y. Ezra
, I. Levy
, M. Mazor
, U. Martinowitz

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.

Original language	English
Pages (from-to)	266-267
Number of pages	2
Journal	Archives of Gynecology and Obstetrics
Volume	268
Issue number	4
DOIs	https://doi.org/10.1007/s00404-002-0409-1
State	Published - Oct 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Factor VIIa
Hemorrhage
Postpartum hemorrhage

Access to Document

10.1007/s00404-002-0409-1

Cite this

@article{83d598f37d5244f58095c6f204b43248,

title = "Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)",

abstract = "Recombinant activated factor VII (rFVIIa, NovoSeven{\textregistered}) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.",

keywords = "Factor VIIa, Hemorrhage, Postpartum hemorrhage",

author = "S. Segal and Shemesh, \{I. Y.\} and R. Blumenthal and B. Yoffe and N. Laufer and Y. Ezra and I. Levy and M. Mazor and U. Martinowitz",

year = "2003",

month = oct,

doi = "10.1007/s00404-002-0409-1",

language = "אנגלית",

volume = "268",

pages = "266--267",

journal = "Archives of Gynecology and Obstetrics",

issn = "0932-0067",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

AU - Segal, S.

AU - Shemesh, I. Y.

AU - Blumenthal, R.

AU - Yoffe, B.

AU - Laufer, N.

AU - Ezra, Y.

AU - Levy, I.

AU - Mazor, M.

AU - Martinowitz, U.

PY - 2003/10

Y1 - 2003/10

N2 - Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.

AB - Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.

KW - Factor VIIa

KW - Hemorrhage

KW - Postpartum hemorrhage

UR - https://www.scopus.com/pages/publications/0141867823

U2 - 10.1007/s00404-002-0409-1

DO - 10.1007/s00404-002-0409-1

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0141867823

SN - 0932-0067

VL - 268

SP - 266

EP - 267

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

IS - 4

ER -

Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this